Jazz to Acquire Actio for $820M to Expand Rare Epilepsy Portfolio

Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront to acquire ABS-1230, a potential precision therapy for KCNT1+ epilepsy, which currently has no FDA-approved treatments.